# Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

> **NCT07457918** · PHASE3 · RECRUITING · sponsor: **Verrica Pharmaceuticals Inc.** · enrollment: 600 (estimated)

## Conditions studied

- Common Warts (Verruca Vulgaris)
- Common Warts
- Human Papilloma Virus (HPV)
- Warts

## Interventions

- **COMBINATION_PRODUCT:** Cantharidin

## Key facts

- **NCT ID:** NCT07457918
- **Lead sponsor:** Verrica Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-11
- **Primary completion:** 2028-04-30
- **Final completion:** 2028-05-22
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07457918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07457918, "Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07457918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*